Our focus research areas include immuno-oncology, neuro-oncology, the tumour microenvironment, tumour metabolism and tumour genetics. Dedicated expertise is available for selected cancer types including brain cancers and haematological malignancies. In addition, LIH hosts Luxembourg’s National Cancer Registry (Registre National du Cancer, RNC), a core component of the national cancer control strategy. The RNC is a population-based cancer registry (PBCRs) and collects information from multiple sources on all new cancers diagnosed or treated in Luxembourg for public health and research purposes.

LIH also conducts research on cancer prevention and care, including risk factor identification and health data expertise, and digital biomarkers, using Patient-reported outcome measures (PROMs) and patient-reported experience measures (PREMS) to improve cancer patient outcomes (“Luxembourg to speed up the standardisation of clinical data” and Colive Voice project).

LIH investigates mechanistic processes that are fundamental for cancer initiation, progression and resistance to treatment. These include reciprocal crosstalk between tumour and non-neoplastic cells, cancer genetics and epigenetics, resistance to treatment, cancer metabolism and processes of invasion and metastasis.

The goal is to understand the biology of the disease in order to advance novel concepts from the prediction of response to therapy, the identification of novel targets for treatment to the development of innovative treatment approaches. A particular focus lies in developing and improving immunotherapies.

In parallel LIH has built up a strong expertise in selected cancer types, including brain cancer and blood malignancies.

Team Members:
Ulf NEHRBASS
Claudine Backes
Stefan Debast
Irina Carpusca